Drugs / PEDylated Recombinant Human Endostatin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01260025 | Sep 2009 → Jan 2011 | Mammastatin | Sun Yat-sen University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEDylated Recombinant Human Endostatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01260025 ↗ |
| Known as | M2ES | “The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.” NCT01260025 ↗ |